latest news releases from the newsroom
Optimer Pharmaceuticals, Inc.
Optimer Pharmaceuticals Regains North American Rights to Difimicin (Par-101/Opt-80)
SAN DIEGO, Feb. 27, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the company has regained North American rights to Difimicin (PAR-101/OPT-80) from Par Pharmaceutical Companies, Inc. Difimicin is the company's lead antibiotic product candidate for the treatment of Clostridium difficile-associated diarrhea, or CDAD. With this buy-back transaction, the collaboration agreement between the two companies dated April 29, 2005, is no longer effective.
WCI Communities, Inc.
WCI Releases Fourth Quarter and Full Year 2006 Earnings
BONITA SPRINGS, Fla., Feb. 27, 2007 (PRIME NEWSWIRE) -- WCI Communities, Inc. (NYSE:WCI), a leading builder of traditional and tower residences in highly amenitized lifestyle communities, today reported its results for the fourth quarter and full year ended December 31, 2006. For the twelve months ended December 31, 2006, net income fell to $9.0 million compared with $186.2 million in 2005, while diluted earnings per share (EPS) declined to $0.21 from $4.00 a year ago. If $139.5 million in pre-tax charges for asset impairments and land acquisition termination costs (collectively "Write-offs") were excluded, EPS would have approximated $2.16. Revenues for 2006 totaled $2.05 billion vs. $2.60 billion a year ago. Overall company gross margin for 2006 equaled 12.2% or 19.0% before Write-offs. In 2005, the total company gross margin was 23.0%.